Legend Biotech (LEGN) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Legend Biotech (LEGN) over the past year, gaining 30.1% versus a loss of 39.1%. Over five years, OGN leads with a -60.5% price change compared with -63.2% for LEGN. Organon is the larger company by market cap ($3.62 billion vs $3.60 billion), about 1.0 times the size, while Legend Biotech is growing revenue faster (+64.0% vs -2.9%).
On valuation, Organon trades at a lower forward P/E (3.8x vs 17.6x for Legend Biotech). Organon pays a dividend yielding 0.58%, while Legend Biotech does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -28.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | OGN |
|---|---|---|
| Share price | $18.51 | $13.80 |
| Market cap | $3.60B | $3.62B |
| 1-day change | -3.22% | +0.04% |
| YTD return | -12.05% | +92.33% |
| 1-year return | -39.13% | +30.09% |
| 5-year return | -63.17% | -60.48% |
| P/E ratio (TTM) | — | 17.69 |
| Forward P/E | 17.62 | 3.82 |
| EPS (TTM) | $-0.52 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $1.03B | $6.22B |
| Revenue growth (YoY) | +64.04% | -2.92% |
| Net income (latest FY) | $-296.80M | $187.00M |
| Gross margin | 61.41% | 53.30% |
| Operating margin | -13.27% | — |
| Net margin | -28.85% | 3.01% |
| 52-week high | $37.50 | $13.80 |
| 52-week low | $16.24 | $5.69 |
| Distance from 52-week high | -50.65% | -0.04% |
| Analyst consensus | buy | none |
| Avg. price target upside | +151.28% | -18.45% |
| Average volume | 2.36M | 2.64M |
| Shares outstanding | 194.49M | 262.61M |
| Employees | 3,200 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed LEGN by 69.2 percentage points over the past year.
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -28.8 cents for Legend Biotech.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs -2.92%).
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
LEGN vs OGN FAQ
Which is bigger, Legend Biotech or Organon?
Organon (OGN) is larger, with a market capitalization of $3.62B compared with $3.60B for Legend Biotech (LEGN).
Which stock has performed better over the past year, LEGN or OGN?
OGN returned +30.09% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Legend Biotech or Organon?
Organon pays a dividend yielding 0.58%, while Legend Biotech does not currently pay a regular dividend.
Are Legend Biotech and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.